Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China

Pengcheng Gua School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaView further author information

Peng Lub Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, ChinaView further author information

Hui Dingb Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, ChinaView further author information

Qiao Liub Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, ChinaView further author information

Xiaoyan Dingb Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, ChinaView further author information

Yongfa Chena School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, ChinaCorrespondence[email protected]
View further author information

Limei Zhub Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, ChinaCorrespondence[email protected]
View further author information

show all

Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date